Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary CryptoMapTM platform.
All the latest company news, press releases and updates from Epitopea.

Our Science

Revealing Novel Targets For Next Generation Immunotherapies
Learn More

CryptoMapTM

We believe improved cancer therapies are needed to truly transform the lives of cancer patients. We are developing accessible off-the-shelf RNA cancer immunotherapies that we believe will inspire a more durable outcome for cancer patients.
Watch video
Our innovative platform, CryptoMapTM has been optimized to enable the identification of shared, aberrantly expressed tumor-specific antigens (aeTSA), known as CryptigenTM TSAs.
Given these proprietary CryptigenTM TSAs are uniquely expressed and presented by cancer cells and are broadly shared across patients with the same tumor, they provide a tumor-specific targeted rationale for the development of RNA-based immunotherapies that are shared across broad patient populations.

CryptigenTM TSAs are hidden antigens that have largely escaped detection, but their potential impact and significance have been brought to light through the discovery research of Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer of UdeM.

We use our CryptoMapTM discovery platform to ‘reveal’ these hidden CryptigenTM TSAs, based on an empirically-anchored platform that leverages spatial immunopeptidomics, genomics, and systems bioinformatics.

Typically, our CryptoMapTM technology identifies around 100 aberrantly expressed tumor specific antigens per tumor type, which, when compared to current approaches, has the potential to provide more antigens. This allows us to prioritize aeTSAs on the basis of optimal expression and effective recognition by the immune system, which we believe is critical for recognition and destruction of cold tumors.

Therapeutic Focus

We are accelerating the advancement of our pre-clinical pipeline into novel RNA-based cancer immunotherapeutics with durable patient benefits. Our tumor specific, off the shelf RNA-based immunotherapeutic approach means it is possible to optimize treatment for the greatest immune response and greatest coverage, maximising accessibility.
Our CryptigenTM TSAs have the potential to transform the development of off-the-shelf cancer vaccines and the landscape of difficult to treat cancers across a broader patient population.

We are developing a pipeline of RNA assets for use as immunotherapeutics, in preparation for first in human studies in 2026

Publications


Title Year Journal Authors View

Breast cancer immunopeptidomes contain numerous shared tumor antigens

2024 The Journal of Clinical Investigation Eralda Kina, Et al View

Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers

2022 Cell Reports Anca Apavaloaei, Et al View

Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability

2022 MCP Online Jenna Cleyle, Et al View

Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes

2021 Immunity: A Cell Press journal Grégory Ehx, Et al View

Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer

2020 Cancer Immunology Research Qingchuan Zhao, Et al View

Noncoding regions are the main source of targetable tumor-specific antigens

2018 Science Translational Medicine Céline M. Laumont, Et al View


Revealing Novel Targets For Next Generation Immunotherapies
© 2022 – 2024 Epitopea Ltd | All Rights Reserved
Created by FDM Digital
film-play